Biocardia 

Biocardia 

Yahoo Finance • last month

Pre-Market Movers: TNGX, WOK, GOCO Set The Path

(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, hinting at possible breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. Price swings ahead of t... Full story

Yahoo Finance • last month

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.6% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • last month

BioCardia: FDA Says CardiAMP HF II May PMA For Cell Therapy In Ischemic HFrEF; Stock Up

(RTTNews) - BioCardia, Inc. (BCDA) announced that the U.S. FDA has confirmed the company's pivotal Phase 3 CardiAMP Heart Failure II (HF II) trial may serve as the basis for a Premarket Approval (PMA) application for its CardiAMP Cell Ther... Full story

Yahoo Finance • 2 months ago

BioCardia Aligns With FDA On Helix Transendocardial Delivery Catheter Marketing Pathways

(RTTNews) - BioCardia Inc. (BCDA), a clinical-stage regenerative medicine company, on Friday announced alignment with the U.S. food and drug administration after a pre-submission meeting on the Helix transendocardial delivery catheter syst... Full story

Yahoo Finance • 4 months ago

BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a cor... Full story

Yahoo Finance • 4 months ago

BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA

SUNNYVALE, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted... Full story

Yahoo Finance • 7 months ago

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it will participat... Full story

Yahoo Finance • 8 months ago

BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of... Full story

Yahoo Finance • 8 months ago

BioCardia, Inc. Q3 Loss Decreases, Beats Estimates

(RTTNews) - BioCardia, Inc. (BCDA) released Loss for third quarter that decreased from the same period last year and beat the Street estimates. The company's earnings came in at -$1.48 million, or -$0.24 per share. This compares with -$... Full story

Yahoo Finance • 8 months ago

BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for t... Full story

Yahoo Finance • 8 months ago

BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corp... Full story

Yahoo Finance • 9 months ago

BioCardia Inc. (BCDA): 2025 Product Pipeline and Strategy Analysis Report

Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "BioCardia Inc. (BCDA) - Product Pipeline Analysis, 2025 Update" has been added to ResearchAndMarkets.com's offering. BioCardia Inc is at the forefront of regenerative medicine, focusing on... Full story

Yahoo Finance • 9 months ago

BioCardia Regains Compliance with Nasdaq Listing Requirements

SUNNYVALE, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has regained compliance w... Full story

Yahoo Finance • 10 months ago

BioCardia Announces Pricing of Up To $12 Million Public Offering

SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA] (“BioCardia” or the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today... Full story

Yahoo Finance • 10 months ago

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint... Full story

Yahoo Finance • 10 months ago

Notable Wednesday Option Activity: CLSK, BKD, AVXL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in CleanSpark Inc (Symbol: CLSK), where a total volume of 108,050 contracts has been traded thus far today, a contract volum... Full story

Yahoo Finance • 10 months ago

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

SUNNYVALE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- - BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that BioCardia’s Pr... Full story

Yahoo Finance • 11 months ago

BioCardia outlines regulatory milestones and targets FDA and PMDA submissions for CardiAMP and Helix in Q4 2025

Earnings Call Insights: BioCardia, Inc. (BCDA) Q2 2025 MANAGEMENT VIEW * Peter A. Altman, President and CEO, reported the completion of the CardiAMP Heart Failure trial and noted its primary outcomes were presented as a late-breaking c... Full story

Yahoo Finance • 11 months ago

BioCardia GAAP EPS of -$0.40

* BioCardia press release [https://seekingalpha.com/pr/20196192-biocardia-reports-second-quarter-2025-business-highlights-and-financial-results] (NASDAQ:BCDA [https://seekingalpha.com/symbol/BCDA]): Q2 GAAP EPS of -$0.40. * Net cash us... Full story

Yahoo Finance • 11 months ago

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

SUNNYVALE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for t... Full story